Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes

Immunological Reviews

Volumn 161, Issue , 1998, Pages 27-42

  Franco, Rafael ^a   Valenzuela, Agustín ^a   Lluis, Carmen ^a   Blanco, Julià ^b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT PASTEUR   (France)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; DIPEPTIDYL PEPTIDASE IV; LYMPHOCYTE ENZYME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMBINED IMMUNODEFICIENCY; HUMAN; IMMUNOCOMPETENT CELL; LYMPHOCYTE; MOLECULAR INTERACTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PURINE METABOLISM; REVIEW; T LYMPHOCYTE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADENOSINE DEAMINASE; ANIMALS; HUMANS; IMMUNE SYSTEM; LYMPHOCYTES;

EID: 0031908810     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1998.tb01569.x     Document Type: Review

References (105)

1. Hershfield MS, Mitchell BS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York: McGraw-Hill; 1995. p. 1725-1768.
2. Tischfield JA, Creagan RP, Nichols EA, Ruddle FH. Assignment of a gene for adenosine deaminase to human chromosome 20. Hum Hered 1974;24:1-11.
3. Phillip T, et al. Regional assignment of the ADA locus 20q13.2 qtr by gene dosage studies. Cytogenet Cell Genet 1980;27:187-189.
4. Petersen MB, Tranebjaerg L, Tommerup N, Nygaard P, Edwards H. New assignment of the adenosine deaminase gene locus to chromosome 20q13.11 by study of a patient with interstitial deletion 20q. J Med Genet 1987;24:93-96.
5. Wiginton DA, et al. Complete sequence and structure of the gene for human adenosine deaminase. Biochemistry 1986;25:8234-8244.
6. Daddona PE, Shewach DS, Kelley WN, Argos P, Markham AF, Orkin SH. Human adenosine deaminase: cDNA and complete primary sequence. J Biol Chem 1984;259:12101-12106.
7. Ingolia DE, Al-Ubaidi MR, Bigo HA, Kellems RE, Wright DA, Yeung C-Y. Molecular-cloning of the murine adenosine-deaminase gene from a genetically enriched source: identification and characterization of the promoter region. Mol Cell Biol 1986;6:4458-4466.
8. 8Asn substitution results in the adenosine deaminase (ADA) genetic polymorphism (ADA-2 allozyme). Occurrence on different chromosomal backgrounds and apparent intragenic crossover. Ann Hum Genet 1994;58:1-9.
9. Spencer N, Hopkinson DA, Harris H. Adenosine deaminase polymorphism in man. Ann Hum Genet 1968;32:9-14.
10. Conway EJ, Cooke R. The deaminases of adenosine and adenylic acid in blood and tissues. Biochem J 1939;33:479-492.
11. Centelles JJ, Franco R, Bozal J. Distribution of adenosine deaminase in some rat tissues: inhibition by ethanol and dimethylsulfoxide. Comp Biochem Physiol 1987;86B: 95-98.
12. Trotta PP, Balis ME. Structural and kinetic alterations in adenosine deaminase associated with the differentiation of rat intestinal cells. Cancer Res 1977;37:2297-2305.
13. Ma DDF, et al. Distribution of terminal deoxynucleotidyl transferase and purine deagradative and synthetic enzymes in subpopulations of human thymocytes. J Immunol 1982;129:1430-1435.
14. Massaia M, et al. Enzymes of purine metabolism in human peripheral lymphocyte subpopulations. Clin Exp Immunol 1982;50:148-154.
15. Mills GC, Schmalstieg FC, Trimmer KB, Goldman AS, Goldblum RM. Purine metabolism in adenosine deaminase deficiency. Proc Natl Acad Sci USA 1976;73:2867-2871.
16. Dunn DB, Hall RH. Natural occurrence of the modified nucleosides. In: Fasman GD, ed. Handbook of Biochemistry and Molecular Biology. 3rd ed. Cleveland: CRC Press; 1975. p. 65-215.
17. Hall RH. Modified nucleosides: physical properties, chemical synthesis and natural occurrence. In: The modified nucleosides in nucleic acids. New York: Columbia University Press; 1975. p. 17-185.
18. Hirschhorn R, et al. Increased excretion of modified adenine nucleosides by children with idenosine deaminase deficiency. Pediatr Res 1982;16:362-369.
19. Hall RH, Alam NS, McLenna BD, Terrine C, Guerin J. N6-(Δ2-isopentenyl)adenosine: its conversion to inosine, catalyzed by adenosine amino hydrolases from chicken bone marrow and calf intestinal mucosa. Can J Biochem 1971;49:623-630.
20. Zielke CL, Suelter CH. Purine, purine nucleoside and purine nucleotide amino hydrolases. In: Boyer PD, ed. The Enzymes. Vol. 4. New York: Academic Press; 1971. p. 54-64.
21. Wiginton DA, Coleman MS, Hutton JJ. Purification, characterization and radioimmunoassay of adenosine deaminase from human leukaemic granulocytes. Biochem J 1981;195:389-397.
22. Centelles JJ, Franco R, Bozal J. Purification and partial characterization of brain adenosine deaminase: inhibition by purine compounds and by drugs. J Neurosci Res 1988;19:258-267.
23. Van der Weyden MB, Kelley WN. Human adenosine deaminase: distribution and properties. J Biol Chem 1976;251:5448-5456.
24. Wilson DK, Rudolph FB, Quiocho FA. Atomic structure of adenosine deaminase complexed with a transition-state analog: Understanding catalysis and immunodeficiency mutations. Science 1991;252:1278-1284.
25. Wilson DK, Quiocho FA. A pre-transition-state mimic of an enzyme-X-ray structure of adenosine-deaminase with bound 1-deazaadenosine and zinc-activated water. Biochemistry 1993;32:1689-1694.
26. Orozco M, Canela FJ, Franco R. Theoretical study of the hydroxyl nudeophilic attack on the 6-aminopyrimidine molecule: Functional implications in the reaction mechanism of nucleoside deaminative enzymes. J Org Chem 1990;55:2630-2637.
27. Orozco M, Canela EI, Franco R. A quantum chemical study of the enzymatic deamination of benzoadenine derivatives. A theoretical model of the interactions occurring between nucleosides and the active site of adenosine deaminase. Eur J Biochem 1990;188:155-163.
28. Smyth JF, Prentice HG, Proctor S, Hoffbrand AV. Deoxycoformycin in the treatment of leukemias and lymphomas. Ann N Y Acad Sci 1985;451:123-128.
29. Spiers ASD. The activity of deoxycoformycin (pentostatin) in refractory leukemias and lymphomas. Ann N Y Acad Sci 1985;451:138-141.
30. Johnston JB, et al. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2′-deoxycoformycin. Cancer Res 1986;46:2179-2184.
31. Glazer RI. Adenosine deaminase inhibitors: their role in chemotherapy and immunosuppression. Cancer Chemother Pharmacol 1980;4: 227-235.
32. O'Brien WJ, Taylor JL, Brothan SJ. Adenosine deaminase in herpes simplex virus induced corneal stromal disease. Curr Eye Res 1987;6:13-18.
33. Adamson RH, Zaharevitz DW, Johns DG. Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2′-deoxycoformycin. Pharmacology 1977;15:84-89.
34. Cass CE, Au-Yeung TH. Enhancement of 9-β-D-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2′-deoxycoformycin. Cancer Res 1976;36:1486-1491.
35. Glazer RI, Lott TJ, Peale AL. Potentiation by 2′-deoxycoformycin of the inhibitory effect by 3′-deoxyadenosine (cordycepin) on nuclear RNA synthesis in L1210 cells in vitro. Cancer Res 1978;38:2233-2238.
36. Iliakis G, Ngo FQH. Effects of adenosine deaminase inhibitor 2′-deoxycoformycin on the repair and expression of potentially lethal damage sensitive to β-ara A. Radiat Environ Biophys 1985;24:81-88.
37. Johns DG, Adamson RH. Enhancement of the biological activity of cordycepin (3′-deoxyadenosine) by the adenosine deaminase inhibitor 2′-deoxycoformycin. Biochem Pharmacol 1976;25:1441-1444.
38. LePage GA, Worth LS, Kimball AP. Enhancement of the antitumor activity of arabinofuranosyladenine by 2′-deoxycoformycin. Cancer Res 1976;36:1481-1485.
39. Andy RJ, Kornfeld R. The adenosine deaminase binding protein of human skin fibroblasts is located on the cell surface. J Biol Chem 1982;257:7922-7925.
40. Trams EG, Lauter CJ. Adenosine deaminase of cultured brain cells. Biochem J 1975;152:681-687.
41. Franco R, Canela EI, Bozal J. Heterogeneous localization of some purine enzymes in subcellular fractions of rat brain and cerebellum. Neurochem Res 1986;11:423-435.
42. Dinjens WNM, et al. Cell surface adenosine deaminase (ADA) and its complexing protein (ADCP) in human T lymphoid cells. Adv Exp Med Biol 1986;195B: 407-414.
43. Bielat K, Tritsch GL. Ecto-enzyme activity of human erythrocyte adenosine deaminase. Mol Cell Biochem 1989;86:135-142.
44. Franco R, Aran JM, Matutes E, Colomer D, Vives-Corrons J-L. Association of adenosine deaminase with erythrocyte and platelet plasma membrane. An immunological study at light and electron microscopy. J Histochem Cytochem 1990;38:653-658.
45. Aran JM, Colomer D, Matutes E, Vives-Corrons JL, Franco R. Presence of adenosine deaminase on the surface of mononudear blood cells: immunochemical localization using light and electron microscopy. J Histochem Cytochem 1991;39: 1001-1008.
46. Meghji P, Middleton K, Hasall CJ, Phillips MI, Newby AC. Evidence for extracellular deamination of adenosine in the rat heart. Int J Biochem 1988;20:1335-1341.
47. Martín M, Huguet J, Centelles JJ, Franco R. Expression of ectoadenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as co-stimulatory molecule. J Immunol 1995;155:4630-4643.
48. Vives-Corrons JL, et al. Combined assay of adenosine deaminase, purine nucleoside phosphorylase and lactate dehydrogenase in the early clinical evaluation of B-chronic lymphocytic leukemia. Am J Hematol 1988;27:157-162.
49. Senesi S, Freer G, Gasperini M, Batoni G, Campa M. Complete release of adenosine deaminase from mouse lymphocytes stabilized by low-pH acetate. Biochim Biophys Acta 1988;968:59-68.
50. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto M. Direct association of adenosine deaminase with a T cell activation antigen CD26. Science 1993;261:466-469.
51. Ciruela F, Saura C, Canela EI, Mallol J, Lluis C, Franco R. Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. FEBS Lett 1996;380:219-223.
52. 1 adenosine receptors in pig brain cortical membranes. J Neurochem 1996;66:675-682.
53. Fleischer B. CD26: a surface protease involved in T-cell activation. Immunol Today 1994;15:180-184.
54. Torimoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF, Morimoto C. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol 1991;147:2514-2517.
55. Blanco J, Marié I, Callebaut C, Jacotot E, Krust B, Hovanessian AH. Specific binding of adenosine deaminase but not HIV-transactivator protein Tat to human CD26. Exp Cell Res 1996;225:102-111.
56. De Meester I, et al. Binding of adenosine deaminase to the lymphocyte surface via CD26. Eur J Immunol 1994;24:566-570.
57. Plana M, et al. Induction of interleukin-2 (IL-2) and interferon γ and enhancement of IL-2 receptor expression by a CD26 monoclonal antibody. Eur J Immunol 1991;21:1085-1088.
58. Nagy JI, Yamamoto TY, Uemura H, Schrader WE. Adenosine deaminase in rodent median eminence: detection by antibody to the mouse enzyme and colocalization with adenosine deaminase complexing protein (CD26). Neuroscience 1996;73:459-471.
59. Dong RP, et al. Characterization of adenosine deaminase binding to human CD26 on T cells and its biological role in immune response. J Immunol 1996;156:1349-1355.
60. Ramos-Morales F, et al. Adenosine deaminase is a specific partner for the Grb2 isoform Grb3-3. Biochem Biophys Res Commun 1997;237: 735-740.
61. Fath I, et al. Cloning of a Grb2 isoform with apoptotic properties. Science 1994;264:971-974.
62. Tucker AL, Linden J. Cloned receptors and cardiovascular responses to adenosine. Cardiovasc Res 1993;27:62-67.
63. Dalziel HH, Westfall DP. Receptors for adenine nucleotides and nucleosides. Subclassification, distribution and molecular characterization. Pharmacol Rev 1994;46:449-466.
64. Olah ME, Ren H, Stiles GL. Adenosine receptors: protein and gene structure. Arch Int Pharmacodyn Ther 1995;329: 135-150.
65. Palmer TM, Stiles GL. Adenosine receptors. Neuropharmacology 1995;34:683-694.
66. 3H]chloroadenosine to rat brain cortical membranes. Can J Physiol Pharmacol 1980;58:576-579.
67. 3H]chloroadenosine. Int J Biochem 1982;14:399-402.
68. 3H]chloroadenosine, a stable analog of adenosine. Proc Natl Acad Sci USA 1980;77:6892-6896.
69. 3H]chloroadenosine to rat brain synaptic membranes. Eur J Pharmacol 1980;64:369-370.
70. Phillis JW, Wu PH. The role of adenosine and its nucleotides in central synaptic transmission. Prog Neurobiol 1981;16:187-239.
71. i adenosine receptors in brain membranes. Mol Pharmacol 1984;26:1-9.
72. 1 adenosine receptor from pig brain. Characterization and evidence of the role of the cell membrane on the coexistence of high and low affinity states. J Neurosci Res 1990;26:461-473.
73. 1 adenosine receptors. Biochemistry 1996;35:3007-3015.
74. Chan TS. Purine excretion by mouse peritoneal macrophages lacking adenosine deaminase activity. Proc Natl Acad Sci USA 1979;76:925-929.
75. Sayós J, et al. Regulation of nitrobenzylthioinosme-sensitive adenosine uptake by cultured kidney cells. Am J Physiol 1994;36: F758-F766.
76. Ruers TJM, Buurman WA, Van der Linden CJ. 2'deoxycoformycin and deoxyadenosine affect IL-2 production and IL-2 receptor expression of human T cells. J Immunol 1987;138:116-121.
77. Kizaki H, Shimada H, Ohsaka F, Sakurada T. Adenosine, deoxyadenosine and deoxyguanosine induce DNA cleavage in mouse thymocytes. J Immunol 1988;141:1652-1658.
78. Carrera CJ, Saven A, Piro LD. Purine metabolism of lymphocytes. New Drug Ther 1994;8:357-381.
79. Ullman B, Gudas LJ, Cohen A, Martin DW Jr. Deoxyadenosine metabolism and cytotoxicity in culture mouse T lymphoma cells: A model for immunodeficiency disease. Cell 1978;14:365-370.
80. Hershfield MH, Kredich NM. Resistance of an adenosine kinase deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth, S-adenosylhomocysteine hydrolase inactivation, and dATP accumulation. Proc Natl Acad Sci USA 1980;77:4292-4295.
81. Ullman B, Levinson BB, Hershfield MS, Martin DW Jr. A biochemical genetic study of the role of specific nucleoside kinases in deoxyadenosine phosphorylation by cultured human cells. J Biol Chem 1981;256:848-858.
82. Catania MV, Sorino MA, Rampello L, Canonico PL, Nicoletti F. Adenosine deaminase increases release of excitatory amino acids through a mechanism independent of adenosine depletion. Neuropharmacology 1991;30:153-159.
83. Martin M, et al. Surface expression of adenosine deaminase in mitogen-stimulated lymphocytes. Clin Exp Immunol 1993;93:286-291.
84. Bour S, Geleziunas R, Wainberg MA. The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev 1995;59:63-93.
85. D'Souza MP, Harden VA. Chemokines and HIV-1 second receptors. Nat Med 1996;2:1293-1300.
86. Oravecz T, et al. CD26 expression correlates with entry, replication and cytopathidty of monocytotropic HIV-1 strains in a T-cell line. Nat Med 1995;1:919-926.
87. + cells. Science 1993;262:2045-2052.
88. Broder C, et al. CD26 antigen and HIV fusion? Science 1994;264:1156-1160.
89. Valle Blazquez M, et al. Selective decrease of CD26 expression in T cells from HIV-1-infected individuals. J Immunol 1992;149:3073-3077.
90. + T cells. Virology 1996;223:318-328.
91. Chin LT, Duenas M, Levi M, Hinkula J, Wahren B, Borrebaek CAK. Molecular characterization of a human anti-HIV monoclonal antibody revealed a CD26-related motif in CDR2. Immunol Lett 1995;44:25-30.
92. Cefai D, Debre P, Kaczorek M, Idziorek T, Autran B, Bismuth G. Human immunodeficiency virus-1 glycoprotein gp120 and gp120 specifically inhibit the CD3/T cell antigen receptor phosphoinositide transduction pathway. J Clin Invest 1990;86:2117-2124.
93. + T lymphocytes by inhibiting interleukin-2 mRNA. Proc Natl Acad Sci USA 1990;87:2379-2383.
94. Morio T, Chatila T, Geha RS. HIV glycoprotein gp120 inhibits TCR-CD3-mediated activation of fyn and lck. Int Immunol 1996;9:53-64.
95. Valenzuela A, et al. Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope gp120 and viral particles. J Immunol 1997;158:3721-3729.
96. Valenzuela A, Blanco J, Krust B, Franco R, Hovanessian AG. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells. J Virol 1997;71:8289-8298.
97. Franco R, et al. Cell surface adenosine deaminase: much more than an ectoenzyme. Prog Neurobiol 1997;52:283-294.
98. Chechik BE, Schrader WP, Fernandes B, Sengupta S, Gelfand EW. Association of adenosine deaminase with differentiation of normal and leukemic T and B lymphocytes. Ann N Y Acad Sci 1985;431:169-179.
99. Ratech H, Hirschhorn R, Thorbecke GJ. Effects of deoxycoformycin in mice. III A murine model reproducing multi-system pathology of human adenosine deaminase deficiency. Am J Pathol 1985;119:65-72.
100. Barton RW. The effects of an induced adenosine deaminase deficiency on T-cell differentiation in the rat. Cell Immunol 1985;95:297-310.
101. Doherty PJ, et al. Adenosine deaminase and thymocyte maturation. Scand J Immunol 1991;33:405-410.
102. Benveniste P, Cohen A. p53 expression is required for thymocyte apoptosis induced by adenosine-deaminase deficiency. Proc Natl Acad Sci USA 1995;92:8373-8377.
103. Migchielsen AAJ, et al. Adenosine-deaminase-deficient mice die perinatally and exhibit liver-cell degeneration, atelectasis and small-intestinal cell-death. Nat Genet 1995;10:279-287.
104. Wakamiya M, et al. Disruption of the adenosine-deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc Natl Acad Sci USA 1995;92:3673-3677.
105. Jacotot E, et al. Dipeptidyl peptidase IV-β, a novel form of cell surface expressed protein with dipeptidyl peptidase IV activity. Eur J Biochem 1996;239:248-258.